Efficacy of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) by tumor burden - 21/04/16
Patrick Combemale, Centre Leon Bérard, Lyon, France; Reinhard Dummer, Skin Cancer Center University Hospital, Zurich, Switzerland; Michael Migden, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Alexander Guminski, Royal North Shore Hospital, St Leonards, Australia; Karl Lewis, University of Colorado Cancer Center, Denver, CO, United States; Tingting Yi, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Patrick Burnett, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Dalila Sellami, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; John Lear, Manchester Royal Infirmary, Manchester, United Kingdom; Ralf Gutzmer, Medizinische Hochschule Hannover, Hannover, Germany
Le texte complet de cet article est disponible en PDF.| Supported by Novartis Pharma AG, Basel, Switzerland. |
Vol 74 - N° 5S1
P. AB197 - mai 2016 Retour au numéro
Article précédent
- Efficacy of sonidegib in patients with aggressive and nonaggressive subtypes of locally advanced basal cell carcinoma
- Efficacy of sonidegib in patients with metastatic BCC (mBCC)
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?